See more : Air T, Inc. (AIRTP) Income Statement Analysis – Financial Results
Complete financial analysis of Santander Consumer USA Holdings Inc. (SC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Santander Consumer USA Holdings Inc., a leading company in the Financial – Credit Services industry within the Financial Services sector.
You may be interested
- Foxconn Technology Co., Ltd. (2354.TW) Income Statement Analysis – Financial Results
- Trigyn Technologies Limited (TRIGYN.NS) Income Statement Analysis – Financial Results
- Pine Island Acquisition Corp. (PIPP) Income Statement Analysis – Financial Results
- InterPrivate IV InfraTech Partners Inc. (IPVIU) Income Statement Analysis – Financial Results
- Feng Tay Enterprises Co., Ltd. (9910.TW) Income Statement Analysis – Financial Results
Santander Consumer USA Holdings Inc. (SC)
Industry: Financial - Credit Services
Sector: Financial Services
Website: https://www.santanderconsumerusa.com
About Santander Consumer USA Holdings Inc.
Santander Consumer USA Holdings Inc., a specialized consumer finance company, provides vehicle finance and third-party servicing in the United States. It offers vehicle financial products and services, including retail installment contracts and vehicle leases, as well as dealer loans for inventory, construction, real estate, working capital, and revolving lines of credit. The company also provides financial products and services related to recreational and marine vehicles; originates vehicle loans through RoadLoans.com, a web-based direct lending program; purchases vehicle retail installment contracts from other lenders; and services automobile, and recreational and marine vehicle portfolios for other lenders. In addition, it originates private-label loans and leases; and offers personal loans, as well as provides point-of-sale financing. The company was founded in 1995 and is headquartered in Dallas, Texas. Santander Consumer USA Holdings Inc. is a subsidiary of Santander Holdings USA, Inc.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.74B | 6.57B | 6.06B | 5.72B | 5.82B | 6.07B | 5.60B | 3.84B | 2.87B | 2.63B | 2.01B |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 6.74B | 6.57B | 6.06B | 5.72B | 5.82B | 6.07B | 5.60B | 3.84B | 2.87B | 2.63B | 2.01B |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.63B | 2.63B | 2.28B | 2.16B | 1.79B | 1.42B | 1.42B | 574.14M | 361.71M | 369.55M | 249.80M |
| Selling & Marketing | 0.00 | -262.06M | -264.78M | -275.70M | -293.36M | -241.52M | -201.02M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.63B | 2.37B | 2.02B | 1.88B | 1.49B | 1.18B | 1.22B | 574.14M | 361.71M | 369.55M | 249.80M |
| Other Expenses | -6.96B | 4.59B | 4.36B | 4.44B | 4.41B | 4.14B | 3.26B | -2.95B | -1.75B | -1.47B | -1.32B |
| Operating Expenses | -4.33B | 6.96B | 6.38B | 6.32B | 5.91B | 5.32B | 4.48B | -2.37B | -1.39B | -1.10B | -1.07B |
| Cost & Expenses | -4.33B | 6.96B | 6.38B | 6.32B | 5.91B | 5.32B | 4.48B | -2.37B | -1.39B | -1.10B | -1.07B |
| Interest Income | 5.14B | 5.12B | 4.92B | 4.78B | 5.04B | 5.27B | 4.64B | 3.78B | 2.95B | 2.59B | 2.08B |
| Interest Expense | 1.20B | 1.36B | 1.16B | 950.95M | 754.69M | 561.75M | 476.34M | 376.71M | 312.38M | 296.27M | 218.19M |
| Depreciation & Amortization | 2.21B | 1.99B | 1.67B | 1.40B | 1.09B | 833.07M | 825.00M | 188.92M | 187.35M | 258.22M | 124.49M |
| EBITDA | 4.62B | 4.70B | 4.02B | 3.18B | 3.01B | 2.68B | 2.51B | 1.65B | 1.67B | 1.79B | 1.06B |
| EBITDA Ratio | 68.56% | 71.49% | 66.32% | 55.59% | 51.76% | 44.17% | 44.81% | 43.07% | 58.13% | 67.97% | 52.70% |
| Operating Income | 2.41B | 2.71B | 2.35B | 1.77B | 1.92B | 1.85B | 1.69B | 1.46B | 1.48B | 1.53B | 934.25M |
| Operating Income Ratio | 35.80% | 41.23% | 38.79% | 31.04% | 32.94% | 30.44% | 30.09% | 38.15% | 51.60% | 58.15% | 46.50% |
| Total Other Income/Expenses | -1.20B | -1.36B | -1.16B | -950.95M | -754.69M | -561.75M | -476.34M | -378.53M | -292.45M | -276.29M | -218.19M |
| Income Before Tax | 1.21B | 1.35B | 1.19B | 823.51M | 1.16B | 1.29B | 1.21B | 1.09B | 1.19B | 1.25B | 716.06M |
| Income Before Tax Ratio | 17.94% | 20.60% | 19.67% | 14.40% | 19.96% | 21.18% | 21.59% | 28.28% | 41.41% | 47.64% | 35.64% |
| Income Tax Expense | 298.92M | 359.90M | 276.34M | -364.09M | 394.25M | 458.03M | 443.64M | 389.42M | 453.62M | 464.03M | 277.94M |
| Net Income | 910.91M | 994.37M | 915.93M | 1.19B | 766.47M | 827.29M | 766.35M | 697.49M | 715.00M | 768.20M | 438.11M |
| Net Income Ratio | 13.51% | 15.13% | 15.11% | 20.77% | 13.18% | 13.63% | 13.67% | 18.18% | 24.91% | 29.23% | 21.81% |
| EPS | 2.87 | 2.86 | 2.54 | 3.30 | 2.14 | 2.33 | 2.20 | 2.01 | 2.07 | 3.12 | 1.78 |
| EPS Diluted | 2.87 | 2.86 | 2.54 | 3.30 | 2.13 | 2.31 | 2.15 | 2.01 | 2.07 | 3.12 | 1.78 |
| Weighted Avg Shares Out | 317.69M | 347.51M | 360.67M | 359.61M | 358.28M | 355.10M | 348.72M | 346.18M | 346.16M | 246.06M | 245.78M |
| Weighted Avg Shares Out (Dil) | 317.69M | 347.51M | 360.67M | 360.29M | 359.17M | 358.88M | 355.72M | 346.18M | 346.16M | 246.06M | 245.78M |
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in Vienna. The post-hoc analysis from the LIBERTY-CD (Crohn's disease) and LIBERTY-UC (ulcerative colitis) studies suggest that...
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open...
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that the...
Santander Consumer USA Secures Exclusive Multi-Year Agreement with INEOS Automotive
DALLAS--(BUSINESS WIRE)--Santander Consumer USA Inc. (“Santander Consumer”) today announced a new, exclusive multi-year agreement in the U.S. with INEOS Automotive Ltd (“INEOS Automotive”), which will enable it to serve as INEOS Automotive's preferred provider of automobile financial services in the...
Fawad Chaudhry to Appear in Court Today as per IHC Orders
ISLAMABAD: Islamabad High Court (IHC) Ordered Islamabad IS Police on On Monday to present Pakistani Tehreek-e-Insaf (PTI) leader Fawad Chaudhry in court today (Tuesday). Favada was detained by the police. last the week since he left the Supreme Court (SC)...
Imran Khan's Close Aide Fawad Chaudhry Arrested Amid Protests: Report
Pakistan Tehreek-e-Insaf (PTI) Senior Vice-President Fawad Chaudhry has been arrested outside the Supreme Court (SC) in Islamabad on Wednesday, Geo News reported...
Arrest of Fawad Ch outside Supreme Court.
ISLAMABAD: Fawad Chaudhry, Vice President of the Pakistan Tehreek-e-Insaf Organization (PTI), was arrested by police from outside Supreme Court (SC) for 16 IGOs. Fawad Chaudhry attended in Supreme Court building from 12:00 to avoid his arrest. He was immediately arrested...
Venezuela’s president supported Lavrov’s speech at the UN Security Council
Venezuelan President Nicolas Maduro expressed his full support for the speech by the head of the Russian Foreign Ministry, Sergei Lavrov, during the meeting of the UN Security Council (SC) […]...
Polyansky: Russia to return to subject of Nord Stream attacks at UN Security Council
The subject of sabotage on the Russian Nord Stream gas transmission network will be heard more than once on the website of the UN Security Council (SC). Dmitry Polyansky, the […] The post Polyansky: Russia to return to subject of...
Hersh called the expected decision of the UN Security Council on the Russian resolution on Nord Stream
The refusal of the UN Security Council (SC) to accept for consideration a Russian draft resolution calling for an international investigation into the sabotage of the Nord Stream and Nord […] The post Hersh called the expected decision of the...
Source: https://incomestatements.info
Category: Stock Reports